We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Advise on Screening for Viral Contamination in Continuous Manufacturing of Therapeutic Proteins
FDA Issues Advise on Screening for Viral Contamination in Continuous Manufacturing of Therapeutic Proteins
The FDA has posted suggestions for ways to filter out viral contamination during continuous manufacturing of therapeutic proteins, based on studies conducted within the Center for Drug Evaluation and Research.